Sun Pharmaceutical Industries (BOM:524715, NSE:SUNPHARMA) has been assigned a long-term issuer credit rating of Baa1 by Moody's Ratings and BBB+ by S&P Global Ratings, both with stable outlooks, according to a Tuesday exchange filing.
The ratings take into account Sun Pharma's proposed acquisition of Organon & Co., according to the filing.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.